Research Journal of Pharmacy and Technology
SCOPUS
  • Year: 2023
  • Volume: 16
  • Issue: 8

Understanding the global transmission and demographic distribution of Nipah virus (NiV)

  • Author:
  • Md. Rezwan Ahmed Mahedi1,*, Anurag Rawat2, Fazle Rabbi3, K. Suresh Babu4, Elias Salvador Tasayco5, Franklin Ore Areche6, Olga Vicentina Pacovilca-Alejo6, Denis Dante Corilla Flores6, Salomón Vivanco Aguilar6, Fredmoore L. Orosco7, Nikolaos Syrmos8, Mustafa Mudhafar9, Sadia Afrin1, Mst. Mahfuza Rahman10
  • Total Page Count: 7
  • Page Number: 3588 to 3594

1Department of Pharmacy, Comilla University

10Assistant Professor, Department of Pharmacy, Comilla University, Bangladesh

2Associate Professor, Cardiology Himalayan Institute of Medical Science, Jolly GrantDehradun248140UttaranchalIndia

3Australian Computer Society

4Professor, Department of Biochemistry, Symbiosis Medical College for Women, Symbiosis International (Deemed University), Pune

5Universidad Nacional "San Luis Gonzaga" - Peru

6National University of Huancavelica, Huancavelica - Peru

7Industrial Technology Development Institute, Department of Science and Technology, Taguig City, Philippines

8Human Performance and Health, Aristotle University of Thessaloniki, Thesaaloniki, Macedonia, Greece

9Department of Pharmaceutical Chemistry, College of Pharmacy, University of Ahl Al Bayt, 56001, Karbala, Iraq

*Corresponding Author E-mail: rezwanmahed747@gmail.com

Online Published on 2 November, 2023.

Abstract

Nipah virus (NIV) infection was identified in 1998, in Malaysia. The virus belongs to the Paramyxoviridae family. In the past, the virus was spread in Bangladesh, India, as well as Singapore. It affects our nervous system and the respiratory system, which is highly dangerous for our lives. It is caused by an RNA virus and has a high mortality rate. This virus can be transmitted from bats to humans, pigs to humans, or humans to humans. It is conceptualized that fruit bats like Pteropus vampyrus and Pteropus hypomelanus are responsible for transmitting the virus. From 1999 to 2022, there is no approved vaccine and medicines for the treatment of nipah virus infection. The fatality rate of this nipah virus is 75% to 95%. Moreover, NiV B (Bangladesh) is more deathly than NiV M (Malaysia). In present, some vaccines are under trial on pigs, horses and the monkey. In this review we try to focus on the barrier of vaccine and medicine development for this nipah virus.

Keywords

Nipah virus (NIV), Encephalitis, Respiratory system, Pathogenicity, Molecular Epidemiology, Bats, Bangladesh, Etc